The New NRDL Becomes Official: Many New Oncology Drugs Are Listed and Some Immune Drugs Become Affordable
The National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020) (“NRDL”) of China was released by the NHSA and Ministry of Human Resources and Social Security of China.
January 7, 2021
by PharmaSources/Xiaobin
A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019
Information on the top ten best-selling oncology drugs in China and the U.S. in 2019 has recently been released by a related consulting agency of the industry.
December 24, 2020
by PharmaSources/Caicai
Pharmaceutical News of the Week | CPhI.CN - Policies
The National Health Commission of China issued the Administrative Measures for the Clinical Use of Oncology Drugs (Draft for Comment) on July 29 in order to strengthen the administration of the clinical use of medical institutions’ oncology drugs.
August 6, 2020
by PharmaSources/Caicai
Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and world market
The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19 pandemic, China’s situation is gradually stabilizing and improving through the concerted efforts of all to fight the pandemic.
July 3, 2020
by PharmaSources/Xiaobin
A Review of the Anticancer Drugs Approved in China in 2019
A review of the 7 blockbuster innovative oncology drugs approved by the NMPA (National Medical Products Administration of China) in 2019.
February 6, 2020
by PharmaSources/Yefenghong
Sales of generic oncology drugs surge
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028…
February 21, 2019
by europeanpharmaceuticalreview
Acrotech Biopharma to buy seven drugs from Spectrum for $300m
Aurobindo Pharma USA subsidiary Acrotech Biopharma has signed a definitive agreement to buy seven haematology and oncology drugs from Spectrum Pharmaceuticals for a consideration of up to $300m.....
January 21, 2019
by pharmaceutical-technology
Anaeropharma, Chugai come together to create Novel Oncology Drugs
Under the agreement, Anaeropharma and Chugai conduct joint research regarding specific oncology substances by use of Anaeropharma's i-DPS technology and Chugai's technology
October 23, 2018
by biospectrumasia
Novartis hands over global rights for two oncology drugs to Shanghai's Laekna
Novartis has revealed that it has jettisoned two of its clinical stage oncology products along with exclusive global development and commercialisation rights to Shanghai-based biotech firm Laekna.
August 3, 2018
by pharmafile
AstraZeneca's oncology drugs receive regulatory boost
US FDA has granted priority review for its AstraZeneca's candidate that treats leukemia while EU has accepted the Marketing Authorisation Application ) for Lynparza
April 8, 2018
by biospectrumasia
AstraZeneca:2018 Sale Directions from 2017 Financial Report and Chinese Market
Global pharmaceutical enterprises have successively published their 2017 financial reports recently, and there were good and poor results
February 12, 2018
by Shulin Yang
A Review of the Class 1 Oncology Drugs Approved in China in Recent Years
Getting Rid of the Previous Embarrassment of No New Drug in 10 Years
February 7, 2018
by Muzi